2,4- bis(N,N'- di(carboxymethyl)aminomethyl)fluorescein

bone marking fluorescent dye

Also Known As:

DCAF

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Spiro Compounds: 2
      - Fluoresceins: 2
        2,4-bis(N,N'-di(carboxymethyl)aminomethyl)fluorescein: 6
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Xanthenes: 65
      - Fluoresceins: 2
        2,4-bis(N,N'-di(carboxymethyl)aminomethyl)fluorescein: 6
Polycyclic Compounds: 6
- Spiro Compounds: 2
  - Fluoresceins: 2
    - 2,4-bis(N,N'-di(carboxymethyl)aminomethyl)fluorescein: 6

Experts

1.	Deng, Haiteng: 2 articles (03/2019 - 01/2019)
2.	Feng, Shan: 2 articles (03/2019 - 01/2019)
3.	Zhang, Lin: 2 articles (03/2019 - 01/2019)
4.	Arroyo, Sam: 1 article (03/2019)
5.	Cheng, Gong: 1 article (03/2019)
6.	Gong, Yiyi: 1 article (03/2019)
7.	Guo, Lin: 1 article (03/2019)
8.	Jiang, Xu: 1 article (03/2019)
9.	Li, Jin: 1 article (03/2019)
10.	Liu, Xudong: 1 article (03/2019)

Related Diseases

1.	Neoplasms (Cancer) 12/11/2017 - "have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic "D-cyclin activating features (DCAF)" as particularly vulnerable. " 08/01/2014 - "Merlin, a tumor suppressor encoded by the neurofibromatosis type 2 gene, has been shown to suppress tumorigenesis by inhibiting the Cullin 4-RING E3 ubiquitin ligase CRL4(DCAF) (1) in the nucleus. "
2.	Myasthenia Gravis 01/01/2019 - "The development of DCAF molecules makes significant contribution to the progress of targeted therapy, which were demonstrated to eliminate the antibody dependent enhancement (ADE) effect in a Dengue virus (DENV) infection model and to boost the acetylcholine receptor activity in a myasthenia gravis model. " 03/21/2019 - "We demonstrate that DCAF binds the cognate antibody with high selectivity by simultaneously binding to the Fab and Fc regions of IgG. Animal experiments revealed that DCAF molecules diminish the antibody-dependent enhancement effect in a dengue virus infection model, and rescue the acetylcholine receptor by inhibiting the complement cascade in a myasthenia gravis model. "
3.	Infections 01/01/2019 - "Here, we describe a protocol for the synthesis of a DCAF molecule (DCAF1), which can selectively block 4G2 antibody to attenuate ADE effect during Dengue virus infection, and illustrate the binding of DCAF1 to 4G2 antibody by an ELISA assay. " 01/01/2019 - "The development of DCAF molecules makes significant contribution to the progress of targeted therapy, which were demonstrated to eliminate the antibody dependent enhancement (ADE) effect in a Dengue virus (DENV) infection model and to boost the acetylcholine receptor activity in a myasthenia gravis model. " 03/21/2019 - "We demonstrate that DCAF binds the cognate antibody with high selectivity by simultaneously binding to the Fab and Fc regions of IgG. Animal experiments revealed that DCAF molecules diminish the antibody-dependent enhancement effect in a dengue virus infection model, and rescue the acetylcholine receptor by inhibiting the complement cascade in a myasthenia gravis model. "
4.	Carcinogenesis 08/01/2014 - "Merlin, a tumor suppressor encoded by the neurofibromatosis type 2 gene, has been shown to suppress tumorigenesis by inhibiting the Cullin 4-RING E3 ubiquitin ligase CRL4(DCAF) (1) in the nucleus. "
5.	Neurofibromatosis 2 (Neurofibromatosis Type II) 08/01/2014 - "Merlin, a tumor suppressor encoded by the neurofibromatosis type 2 gene, has been shown to suppress tumorigenesis by inhibiting the Cullin 4-RING E3 ubiquitin ligase CRL4(DCAF) (1) in the nucleus. "

Related Drugs and Biologics

1.	Cholinergic Receptors
2.	Cullin Proteins (Cullins)
3.	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)
4.	Neurofibromin 2 (Merlin)
5.	Cyclins
6.	Proteins (Proteins, Gene)
7.	Ligases (Synthetase)
8.	Immunoglobulin G (IgG)
9.	Enzymes
10.	Complement System Proteins (Complement)

Related Therapies and Procedures

1.	Therapeutics